The greatest entrepreneurial opportunities live across the clinical trials value chain; the COVID-19 macroenvironment has highlighted procedural inefficiencies and technological disparities in trial administration. An emerging class of startups now has the opportunity to revamp clinical trials as digitization becomes an urgent priority within the pharma industry.